Pharmaceutical technology · Muscat, Oman

Advanced drug delivery for medicines that are difficult to deliver.

Ibdaa Biotech develops synchronized drug-delivery and transport-engineering technologies through the ADAPT platform portfolio, designed to address poor solubility, limited permeability, drug degradation and complex release requirements. ADAPT combines modular and adaptable technologies across barrier transport, programmed release and long-acting delivery.

Explore ADAPT Discuss a partnership
01ADAPT platform portfolio
02B2B co-development
03Global licensing pathways
Conceptual visualization of precision drug delivery at a biological target
Conceptual visualization · precision delivery
Our platform thesis Solve multiple delivery barriers together.

Formulation science

Translational development

Intellectual property

Commercialization

The company

One company.
A modular, adaptable platform engine.

Rather than depend on a single molecule, Ibdaa’s ADAPT portfolio applies modular and adaptable delivery architectures to generate differentiated formulation and product-development opportunities across multiple therapeutic areas.

Our model connects formulation design, analytical characterization, CMC and pharmacokinetic strategy with intellectual-property development and commercial partnering—creating a disciplined path from concept to value-inflection.

7ADAPT technology areas
2initial validation priorities
1integrated development model
Ibdaa Biotech molecular and circuit emblem

Established in the Sultanate of Oman

Built in Muscat. Designed for global markets.

Ibdaa Biotech is building a translational pathway that links advanced formulation science in Oman with international development, licensing and commercialization partners.

Platform portfolio

ADAPT

Advanced Delivery Systems, Barrier Transport and Programmed Release Technologies

ADAPT brings together modular technologies designed to coordinate drug availability, protection from degradation, barrier transport and programmed release at the intended site and time. Platform selection follows the molecule, route of administration and target product profile.

01
Conceptual epithelial layer showing protected drug availability and transport

Synchronized oral & transmucosal delivery

A delivery technology designed to align drug availability, enzymatic protection and epithelial transport during an intended absorption window.

Initial validation priority
02
Conceptual unfolding mucoadhesive delivery form on a mucosal surface

Sequential mucoadhesive & 4D-printed systems

Stimulus-responsive form factors designed to increase mucosal contact and sequence release for difficult-to-deliver therapeutics.

03
Conceptual hybrid carrier approaching a biological barrier

Adaptive carrier-enhancer systems

Carrier and interface technologies exploring drug stabilization and transport across mucosal, ocular and skin barriers.

04
Distinct coated microbead populations suspended in an oral liquid

Programmable multiparticulate oral liquids

Distinct particle populations designed for timed, staged or synchronized release in an oral liquid.

05
Cutaway of an adaptive tablet matrix containing drug-loaded particles

Adaptive matrices & modified release

Matrix and multiparticulate-in-matrix technologies designed for drug-specific solubility, permeability and release challenges.

06
Conceptual porous depot containing microspheres beneath the skin

Ultralong-acting injectable depot technologies

Porous composite approaches being explored for sustained release of peptides and suitable non-peptide medicines after injection.

Conceptual timed sensory cues and drug release at an oral mucosal surface
07

Sensory-mediated delivery technologies

Exploring whether timed sensory stimulation can be coordinated with drug release at oral, mucosal or skin interfaces.

Conceptual NaV1.8-targeted formulation near a peripheral sensory nerve

Platform application · non-opioid pain

NaV1.8 inhibitor formulation technologies

A candidate-specific provisional application explores how matrix, multiparticulate, oral-liquid and modified-release approaches could be applied to NaV1.8 inhibitors.

Explore the pain feasibility program

Illustrations and animations are conceptual. ADAPT technologies are under development; these descriptions do not imply clinical validation or regulatory approval.

Selected feasibility programs

Translating delivery platforms into partner-ready assets.

Metabolic peptide delivery and NaV1.8-targeted non-opioid pain are Ibdaa’s two initial platform-validation priorities. GLP-2 analog delivery and once-daily acalabrutinib extended release remain exploratory. All programs are at concept or feasibility stage.

01 Concept & feasibility

Initial validation priority · metabolic delivery

Incretin & multi-agonist delivery

GLP-1 / GIP / glucagon class

A differentiated delivery strategy designed to improve patient convenience and therapeutic performance for peptide and multi-agonist medicines.

Current work
Candidate and platform selection · formulation feasibility
U.S. regulatory strategy
Pathway under evaluation, including potential 505(b)(2) where scientifically and legally applicable
Partnering objective
Licensing or co-development following clinical proof-of-concept
02 Concept & feasibility

Initial validation priority · non-opioid pain

NaV1.8-targeted therapy reformulation

Differentiated dosage form, release profile or regimen

A formulation-led opportunity focused on differentiated delivery for a non-opioid, peripherally acting pain-therapy approach.

Current work
Formulation and regulatory feasibility
U.S. regulatory strategy
Potential 505(b)(2), subject to reference-product, bridging, IP/FTO and FDA assessment
Partnering objective
Licensing or co-development following clinical proof-of-concept, potentially after Phase IIa
03 Exploratory feasibility

Intestinal rehabilitation program

GLP-2 analog delivery

Teduglutide · short bowel syndrome

Exploring whether ADAPT-enabled transmucosal delivery of teduglutide could provide a practical route for patients with short bowel syndrome.

Current work
Dose feasibility, peptide stability and mucosal transport assessment
Feasibility gate
Reproducible systemic exposure relative to the injectable reference
Next decision
Advance only after delivery, intellectual-property and regulatory assessment
04 Exploratory feasibility

Targeted oncology program

Once-daily acalabrutinib extended release

BTK inhibitor · modified-release tablet

Evaluating a once-daily tablet concept designed to sustain BTK inhibition across the dosing interval, compared with the marketed twice-daily regimen.

Current work
Release-profile design, stability and pharmacokinetic modeling
Feasibility gate
Comparable exposure and end-of-interval BTK occupancy versus twice-daily dosing
Next decision
Advance only after comparative PK/PD, safety, IP/FTO and regulatory review

Indicative development pathway

Disciplined progression to a licensing inflection point.

  1. 01
    Candidate & formulation feasibilityCurrent stage
  2. 02
    Lead selection & preclinicalPlanned
  3. 03
    IND-enabling & regulatory alignmentPlanned
  4. 04
    Early clinical developmentPlanned
  5. 05
    Clinical proof-of-conceptPartnering target

Proposed development paths depend on scientific results, regulatory and intellectual-property review, funding and partnership decisions.

Development approach

A stage-gated path from delivery problem to partner-ready opportunity.

Development decisions are organized around evidence, intellectual property and a clear commercial endpoint.

  1. 01

    Frame the problem

    Define the molecule, delivery barriers, target product profile and regulatory pathway.

  2. 02

    Design & prototype

    Select the platform architecture and create fit-for-purpose formulation or device concepts.

  3. 03

    Generate evidence

    Build decision-quality analytical, dissolution, permeability and pharmacokinetic strategy packages.

  4. 04

    Advance & partner

    Move selected programs through co-development, licensing or internally led value-inflection milestones.

Initial therapeutic focus

Where delivery innovation can unlock meaningful product value.

  • 01 Metabolic medicine & peptides
  • 02 Intestinal rehabilitation
  • 03 Oncology
  • 04 Pain
  • 05 Central nervous system

Leadership & scientific depth

Built by experienced pharmaceutical innovators.

Ibdaa combines entrepreneurial leadership with deep experience spanning formulation, CMC, quality, regulatory affairs, manufacturing, intellectual property and commercialization.

Founder & scientific leadership

Professor Isa Odidi, MBA, Ph.D., DSc.

Founder · Chief Executive Officer · Chief Scientific Officer

Pharmaceutical scientist, inventor, entrepreneur and board leader with more than 30 years of experience translating drug-delivery science into proprietary technologies, regulated products, manufacturing capabilities and commercial partnerships.

Founder track record

Co-founded and led Intellipharmaceutics, formerly listed on Nasdaq and the Toronto Stock Exchange, and directed integrated development programs that supported U.S. FDA and Health Canada approvals.

Co-inventor & technology contributor

Dr. Amina Odidi, Ph.D.

Technology Development Contributor

Pharmaceutical scientist and inventor with more than 30 years of experience in formulation, analytical development, CMC, quality, regulatory affairs, scale-up, technology transfer and operational leadership.

Industry track record

Co-founded Intellipharmaceutics, formerly listed on Nasdaq and the Toronto Stock Exchange, and led the company as President, Chief Scientific Officer and Chief Operating Officer. She directed integrated development programs that supported U.S. FDA and Health Canada approvals.

Role at Ibdaa

Co-inventor of the patent-pending platforms and joint developer of the core technology.

Advisory network

Scientific, Legal & Business Development Advisors.

An interdisciplinary advisory network supporting scientific execution, quality systems, clinical development, intellectual property, licensing and commercialization.

Scientific advisor

Professor Isa Marte Hussaini, MBA, Ph.D.

Scientific Advisor — Pharmacology, Translational Medicine & Oncology

Professor Hussaini is an internationally experienced pharmacologist and pharmaceutical scientist specializing in molecular pharmacology, neuro-oncology and translational research. He has held academic and research appointments at the University of Virginia, Ahmadu Bello University and the University of Maiduguri, where he served as Dean of Pharmacy. At Ibdaa Biotech, he provides scientific and translational guidance for the company’s advanced drug-delivery technologies.

Advisory focus

  • Pharmacological, mechanistic and PK/PD evaluation of therapeutic candidates
  • Preclinical and translational development strategy, including experimental design
  • Oncology, neuro-oncology and central nervous system applications
  • Biological-barrier transport and advanced drug-delivery platform assessment
  • Scientific evaluation of emerging therapeutic opportunities and research collaborations
Scientific advisor

Dr. Patrick Yat, Ph.D.

Analytical Chemistry Scientist

Analytical chemistry scientist with more than 30 years of teaching and hands-on experience specializing in pharmaceutical analytical R&D, method development and quality systems for complex formulations and drug-delivery technologies.

Areas of expertise

  • Analytical R&D, method development, instrumentation and validation
  • Pharmaceutical quality-control testing
  • Stability and characterization studies
  • CMC support for ANDA, IND and NDA filings
  • Analytical support for formulation and process development
  • Regulatory CTD review
  • Establishment of regulatory-compliant cGMP and cGLP laboratories
  • Regulatory cGMP and cGLP audits
  • USP and Ph. Eur. monograph development
Quality & analytical advisor

Dr. Eveline Ganpo, Ph.D.

Quality Systems, QC/QA & Analytical Sciences Advisor

Pharmaceutical quality and analytical scientist with over 17 years of experience in quality control, quality assurance, auditing and compliance, analytical method development, and characterization of complex pharmaceutical formulations. At Ibdaa, she supports analytical and quality systems for advanced drug-delivery technologies and translational pharmaceutical development programs.

Areas of expertise

  • Quality-control and quality-assurance systems
  • Analytical instrument qualification, method development and validation
  • Data integrity (ALCOA) and compliance with applicable ISO/IEC 17025, GMP, FDA, Health Canada, USP, ICH, BP, ChP and Ph. Eur. requirements
  • Pharmaceutical analytical R&D
  • Drug-substance and drug-product characterization
  • Stability testing and analytical evaluation
  • GMP compliance and quality documentation
  • CMC analytical support
  • Analytical support for formulation and process development
  • Regulatory analytical documentation and data interpretation
Business advisor

Christian Akyempon M.Sc., MBA

Business Development & Commercialization Advisor

Business development and commercialization advisor with more than 30 years of experience supporting strategic growth initiatives, licensing opportunities and commercial partnerships across the pharmaceutical, healthcare and life-sciences sectors.

Areas of expertise

  • Business-development strategy
  • Licensing and partnership development
  • Commercial operations and market strategy
  • Product-commercialization pathways
  • Strategic growth and investor engagement
Legal advisor

John Allport LL.B. · M.A.

Legal Affairs & Licensing Advisor

Legal affairs and licensing consultant with more than 30 years of experience supporting intellectual-property strategy, licensing matters and pharmaceutical innovation transactions, including patent-related legal strategy and commercialization support.

Areas of expertise

  • Patent-litigation strategy
  • Intellectual-property protection and enforcement
  • Licensing and technology-transfer agreements
  • Commercialization and partnership support
  • Strategic IP advice for biotechnology and pharmaceutical platforms
  • Legal support for innovation-driven ventures and product-development programs
Medical advisor

Dr. Enaame Lennox Farrell M.D.

Medical & Clinical Development Advisor

Provides specialized scientific, regulatory and trial-design guidance to help translate advanced delivery platforms from bench development toward clinical testing and commercialization. Advises on clinical trial planning and conduct, the transition to first-in-human (FIH) studies, and the regulatory approval process.

Advisory focus First-in-human readiness & clinical development

Partner with Ibdaa

Let’s solve a difficult delivery problem.

We welcome conversations with pharmaceutical and biotechnology companies, research institutions, development partners and strategic investors.

contact@ibdaabiotech.com

Areas for collaboration

  • Platform validation & feasibility studies
  • Formulation and product co-development
  • Analytical, CMC and PK strategy
  • Licensing & regional commercialization
IBDAA BIOTECHMuscat, Sultanate of Oman

ADAPT Conceptual mechanism

    Measurements needed to test this concept